Biomarkers Consortium – Sarcopenia 2

The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology.

From the Sarcopenia 2 collaborative project stemmed the Sarcopenia Definitions and Outcomes Consortium (SDOC), which established a set of evidence-based criteria that clinicians can use to identify more accurately—through low grip strength and slow gait speed—those at risk of age-related problems involving poor muscle health.

To mark Healthy Aging Month this September 2020, Sarcopenia 2 principal investigators describe the new definitions and what they mean for clinicians caring for older adults and for researchers developing therapies to address functional limitations incurred through sarcopenia.